

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. PB60517	SERIAL NO. 10/572,670
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Asa Elizabeth Gladwin			
		FILING DATE March 20, 2006	GROUP 1624		

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,627,661 B2	9/30/03	Reavill et al.	514	602	
		US20050124628A1	6/9/05	Ahmed et al.	514	253.07	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
		WO 03/035061 A1	5/1/03	PCT				
		WO 03/066056 A1	8/14/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Woolley et al. <i>Neuropharmacology</i> , Vol. 41: 210-219 (2001).
	Mitchell et al., <i>Pharmacol. & Therapeutics</i> , 108: 320-333 (2005).
	Chuang et al., <i>Alzheimer's & Dementia, The Journal of the Alzheimer's Association</i> , 2(3/Supp. 1): S631-S632 (2006).
	London Stock Exchange Announcement – GlaxoSmithKline (GSK) plc, Issued on Thursday, December 13, 2007, New York, New York.
	A Dose Ranging Study to Investigate the Efficacy and Safety of SB-742457 in Alzheimer's Disease. NCT ID NO: NCT00224497 (Verified 2007).
	SB-742457 and Donepezil in Alzheimer's Disease. NCT ID NO: NCT00348192 (2006).
	Garcia-Alloza et al. <i>Neuropsychopharmacology</i> , 29: 410-416 (2004).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.